Woolloongabba, Brisbane, Queensland
Translational Research Institute (TRI) is a medical research facility located at the Princess Alexandra Hospital campus in Woolloongabba in Brisbane, Australia. It was constructed as a seven-storey building for providing support for medical research, administration and teaching.
A 70,000ft2 bio-pharmaceutical manufacturing facility was constructed next to the main TRI building. The new facility accommodates a mammalian biopharmaceutical production facility. The TRI facility is located near the Pharmacy Australia Centre of Excellence.
Construction began in October 2010 and the project was completed in 2012. The land for the facility was donated by the Queensland government.
The biopharmaceutical plant was built at a cost of A$65m ($50m) and was commissioned in October 2013.
The Translational Research Institute project is sponsored by a joint venture between the University of Queensland’s Diamantina Institute, Mater Medical Research Institute (MMRI) and the Princess Alexandra Hospital’s Centres for Health Research, along with the Queensland University of Technology’s Institute of Health and Biomedical Innovation.
The purpose of the project is to increase the investment as well as commercialisation of the medical breakthroughs in Australia, to improve disease-specific research networks of researchers and clinicians. In addition, the project is for improving the health standards of Australians by introducing new medical prophylactic therapies and treatments.
The TRI facilitates the discovery, production and testing of biopharmaceuticals and treatments. The research focus is on cancer, diabetes, obesity and liver diseases, as well as on inflammatory diseases such as HIV, malaria and bone and joint diseases.
The biopharmaceutical manufacturing facility assists new biologic drug developers to outsource the development, as well as provide technical and economical assistance. It houses a pilot plant to help bring newly discovered drugs to pilot commercialisation.
It aims to ensure Australian bioresearch progresses quickly from the lab work to late-stage research in a clinical setting using high-purity material.
The TRI building has a space of 32,000ft2. It has seven storeys, which include four floors of laboratory research, administration and teaching facilities. It houses approximately 700 researchers.
It also has an animal house, a cell therapies facility, staff support spaces, a large lecture theatre and advanced education facilities.
The facility is equipped with two in-building 11kV/415V substations, a 3.2MW, 11kV standby generator, plus 70kW of photovoltaics and intelligent energy. It is also provided with electrical and ICT components, such as a Tier 2.5 tertiary data centre and F/UTP Category 6A structured cabling infrastructure.
Watpac Construction was awarded the building construction contract for the TRI facility in May 2010. The building was designed by Wilson Architects and Donovan Hill.
Aurecon was awarded a contract to provide structural, façade, electrical, dry fire engineering and information and communications technology services for the facility.
The mechanical services contract was awarded to MultiTech Solutions. The contractor was responsible for design, documentation and contract administration.
In May 2010, Netherlands-based medical treatment manufacturer DSM Biologics agreed with the Australian Institute for Bioengineering and Nanotechnology to design, build and operate the biopharmaceutical manufacturing facility at the TRI.
The TRI project was financed by $140 m from the Australian Government, $107m from the Queensland government and $50m from Atlantic Philanthropies. Queensland University of Technology provided $25m and University of Queensland funded $10m.
Australia’s Government agreed to provide funding of $10 million for the biopharmaceutical manufacturing.
Lykan Bioscience opened a purpose-built SMART Manufacturing™ facility for developing cell-based therapies in Hopkinton, Massachusetts, US, in September 2020. The…
Samsung Biologics is planning to expand its manufacturing facilities with the construction of its fourth biopharmaceutical manufacturing plant, P4-Super Plant,…
Evergreen Theragnostics, a radiopharmaceutical contract development and manufacturing organisation (CDMO) based in New Jersey, US, is developing a state-of-the-art radiopharmaceutical…
Aphena Pharma Solutions announced the expansion of its Solid Dose Division in Cookeville, Tennessee, US in September 2020. The project…